Recipharm operations in Italy continue largely unaffected
The impact of COVID-19 on Recipharm’s worldwide operations continue to be monitored daily and to date we have noted limited effect. We anticipate that in the coming days some of our facilities located in the restricted zone of Italy may be operating at a lower capacity than normal. However, at this stage the businesses there continue to receive materials, manufacture and deliver routinely and are thus largely unaffected.
In light of the COVID-19 situation, Recipharm AB will be publishing regular updates on its website providing the latest information about how the company is affected. This can be found at www.recipharm.com
Thomas Eldered, CEO, +46 8 602 52 10
Erik Haeffler, Vice President Manufacturing Services & Head of Sustainability, firstname.lastname@example.org, + 46 8 602 52 85
For media enquiries, please contact Kate Hindhaugh at ramarketing: email@example.com, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.5 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com